4D Molecular Therapeutics Inc expected to post a loss of 86 cents a share - Earnings Preview

4D Molecular Therapeutics

05/05/2025 12:09

4D Molecular Therapeutics Inc FDMT.OQ FDMT.O is expected to show a rise in quarterly revenue when it reports  results on May 7 (estimated) for the period ending March 31 2025

The Emeryville California-based  company is expected to report a 1,266.3% increase in revenue to $382.57 thousand from $28 thousand a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

​LSEG's mean analyst estimate for 4D Molecular Therapeutics Inc is for a loss of 86 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell."

The mean earnings estimate of analysts had risen by about 2.4% in the last three months. ​

Wall Street's median 12-month price target for 4D Molecular Therapeutics Inc is $35.00​, above​ its last closing price of $3.76. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.80
-0.82
-0.90
Missed
-10
Sep. 30 2024
-0.70
-0.70
-0.79
Missed
-12.7
Jun. 30 2024
-0.71
-0.70
-0.63
Beat
10.5​
Mar. 31 2024
-0.75
-0.74
-0.66
Beat
11.3
​​Dec. 31 2023
-0.73
-0.74
-0.75
Missed
-1.2
Sep. 30 2023
-0.66
-0.59
-0.24
Beat
59.6​
Jun. 30 2023
-0.80
-0.81
-0.77
Beat
4.7
Mar. 31 2023
-0.90
-0.89
-0.88
Beat
1.6

This summary was machine generated May 5 at 11:09 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)